Title:Fragment-Based Drug Design of Antitumoral Molecules Polo-like kinase 1 inhibitors: in-silico approach
VOLUME: 18
Author(s):Ayoub Attoui, Widad Sobhi, Nour El Houda Hammoudi and Yacine Benguerba*
Affiliation:Laboratoire des Matériaux Polymères Multiphasiques, LMPMP, Université Ferhat ABBAS Sétif-1, 19000 Sétif,, Laboratory of Applied Biochemistry (LAB), Faculty of Nature and Life Sciences (FNLS), University of Sétif 1, Sétif 19000,, Laboratoire des Matériaux Polymères Multiphasiques, LMPMP, Université Ferhat ABBAS Sétif-1, 19000 Sétif,, Laboratoire des Matériaux Polymères Multiphasiques, LMPMP, Université Ferhat ABBAS Sétif-1, 19000 Sétif
Keywords:Pharmacophore, Virtual screening, Docking, PLK1, Inhibitor, antitumoral.
Abstract:Background: Kinase enzymes are reported to be very implicated in cancer. Polo-like kinase 1 (PLK1) is a protein kinase with a marked role in tumorigenesis and its inhibition is a promising anticancer therapeutic development strategy.
Objective: The purpose of this study was de novo design of new PLK1 inhibitors using in-silico approach.
Method: A virtual compounds library based on known inhibitors was designed using BREED algorithm. Molecules were geometry optimized then filtered according to lead-like properties using QiqProp. Receptor-ligand complex-based pharmacophore model was generated with Phase and used to virtually screen the new virtual database. Glide multistage molecular docking simulations were performed for the resulted compounds followed with a Prime MM-GBSA minimization.
Results: Two compounds (prd-comp 1-2) showed acceptable binding poses with a higher docking score than known inhibitor BI2536. MM-GBSA study confirmed that the leads have better binding energy than reference ligands. All leads bind to the key amino acids Cys133, Leu59, with a focus on molecule prd-comp1, proposed to have better affinity due to direct H-bond with Asp194.
Conclusion: Modifying hydration pattern of target protein by displacing water molecule is suggested to be a promising strategy for designing new PLK1 inhibitors. This applied methodology and the retrieved hits could be useful in the design of potent inhibitors of PLK1 as antitumoral agents.
